Ten years ago, Mayo Clinic investigators published a seminal paper on mild cognitive impairment (MCI). Since then, thousands of papers have appeared in the medical literature focusing on this early stage of cognitive disorders. According to Mayo Clinic scientists, understanding MCI plays a critical role in the efforts to identify the earliest markers of Alzheimers disease and develop therapies to stop or slow its progression. Recently, Mayo Clinic investigators authored a review paper in the Archives of Neurology summarizing both the progress that has been made in the field of MCI and the challenges that remain.
Ronald Petersen, M.D., Ph.D., is a neurologist and director of the Mayo Clinic Alzheimers Disease Research Center.